Dr. Emadi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Medical Center Dr
Morgantown, WV 26506Phone+1 304-598-4500Fax+1 410-328-6896
Education & Training
- Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2007 - 2010
- University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 2005 - 2007
- University of Kentucky College of MedicineInternship, Internal Medicine, 2004 - 2005
- Illinois Institute of TechnologyPhD, Organic Chemistry, 2000 - 2004
- Tehran University of Medical Sciences School of MedicineClass of 1999
Certifications & Licensure
- MD State Medical License 2006 - 2026
- WV State Medical License 2024 - 2026
- OH State Medical License 2005 - 2007
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2012 Jan 13
- 1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML) Start of enrollment: 2014 Apr 01
- Trial of Imatinib for Hospitalized Adults With COVID-19 Start of enrollment: 2020 Jun 02
- Join now to see all
Publications & Presentations
PubMed
- 49 citationsIncidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study.Farid Rashidi, Stefano Barco, Farin Kamangar, Gustavo A. Heresi, Ashkan Emadi
Thrombosis Research. 2021-02-01 - 13 citations1-C Metabolism-Serine, Glycine, Folates-In Acute Myeloid Leukemia.Kanwal Mahmood, Ashkan Emadi
Pharmaceuticals. 2021-02-26 - 8 citationsSafety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.Casey L O'Connell, Maria R Baer, Andreas Due Ørskov, Sunil Kumar Saini, Vu H Duong
Clinical Cancer Research. 2022-12-15
Press Mentions
- MacroGenics : Flotetuzumab (CD123 X CD3) as Salvage Therapy for PIF and ER AML (Aldoss)December 7th, 2020
- $50 Million Gift Will Spur Development of Morgantown Cancer CenterApril 7th, 2024
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: